Eli Lilly and Company $LLY Stock: Cornerstone Advisors LLC Lowers Holdings

Cornerstone Advisors LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 7.8% during the third quarter, HoldingsChannel reports. The firm owned 46,689 shares of the company’s stock after selling 3,943 shares during the quarter. Eli Lilly and Company comprises approximately 1.8% of Cornerstone Advisors LLC’s holdings, making the stock its 10th biggest position. Cornerstone Advisors LLC’s holdings in Eli Lilly and Company were worth $54,023,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of LLY. Bank of America Corp DE acquired a new position in Eli Lilly and Company during the 2nd quarter worth $13,522,666,000. Jupiter Topco LLC bought a new stake in Eli Lilly and Company during the second quarter valued at about $4,667,180,000. Corient Private Wealth LP acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at about $764,116,000. BlackRock Inc. grew its position in shares of Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the last quarter. Finally, State Street Corp grew its position in shares of Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Up 1.2%

LLY opened at $1,444.05 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The firm has a market cap of $1.36 trillion, a price-to-earnings ratio of 46.87, a PEG ratio of 1.71 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,460.00. The firm’s 50-day simple moving average is $1,242.25 and its 200-day simple moving average is $1,110.30.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter in the previous year, the company posted $7.02 earnings per share. Eli Lilly and Company’s quarterly revenue was up 38.6% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is 22.46%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on LLY shares. Jefferies Financial Group raised their target price on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a report on Monday, November 9th. Scotiabank lifted their price target on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 30th. Wells Fargo & Company upped their price target on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $1,413.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,416.64.

Key Stories Impacting Eli Lilly and Company

Here are a few of the latest stories about LLY:

• Positive Sentiment: China approved Lilly’s oral weight-loss drug orforglipron, marketed as Foundayo. As the first GLP-1 weight-loss pill approved in China, it gives Lilly an early foothold in a large market and could broaden access beyond injectable treatments; competition from other drugmakers remains a factor. Reuters: China approves Eli Lilly’s weight loss pill orforglipron
• Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania manufacturing facility intended to make next-generation obesity medicines, including investigational retatrutide. The project supports the company’s broader production expansion, although the site is not expected to begin operations until 2031. Lilly announces Pennsylvania manufacturing facility
• Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.